EDDR1 is a Potential Immunotherapeutic Antigen in Ovarian, Breast, and Prostate Cancer
|Gomathinayagam Sinnathamby1, Jennifer Zerfass1, Julie Hafner1, Peter Block1, Zacharie Nickens1, Amy Hobeika2,
Angeles Alvarez Secord2, H. Kim Lyerly2, Michael A. Morse2 and Ramila Philip1*
|1Immunotope, Inc., 3805 Old Easton Road, Room 211, Doylestown, PA 18902, USA|
|2Duke Comprehensive Cancer Center, Duke University, 25130, Morris Building, Durham|
|Corresponding Author :||Ramila Philip, PhD.
Immunotope, Inc., The Pennsylvania Biotechnology Center 3805
Old Easton Road, Doylestown, PA 18902, USA
E-mail: [email protected]
|Received December 16, 2010; Accepted February 11, 2011; Published February 13, 2011|
|Citation: Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, et al. (2011) EDDR1 is a Potential Immunotherapeutic Antigen in Ovarian, Breast, and Prostate Cancer. J Clin Cell Immunol 2:106. doi:10.4172/2155-9899.1000106|
|Copyright: © 2011 Sinnathamby G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Selection of suitable antigens, preferably targets for cell mediated and humoral immune response is a critical step in the development of cancer vaccines. Cell surface proteins that are over-expressed in cancer cells thus constitute a very attractive class of antigens that can be targeted for effective cancer immunotherapy. Toward this goal, we characterized the relevance of Epithelial Discoidin Domain Receptor 1 (EDDR1) for such targeted therapeutics. EDDR1, a membrane expressed protein associated with adhesion, has recently emerged as a new therapeutic target in several tumor types. In the present study, we analyzed the expression profile of EDDR1 in a variety of normal and cancer cells of human origin by flow cytometry as well as immunohistochemistry. EDDR1 was found to be abundantly expressed on the surface of ovarian, prostate and breast cancer cells but not on the normal counterparts, making it a suitable candidate for antibody mediated therapy. Furthermore, a Human Leukocyte Antigen (HLA) A2-restricted epitope derived from EDDR1 was efficiently presented by various cancer cells to EDDR1 epitope-specific T cells. Collectively, our data present evidence that EDDR1 could be a potential target antigen for immunotherapy.